Novel brain-penetrant inhibitor of G9a methylase blocks Alzheimer's disease proteopathology for precision medication.

Chen, Xian; Xie, Ling; Sheehy, Ryan; Xiong, Yan; Muneer, Adil; Wrobel, John; Park, Kwang-Su; Liu, Jing; Velez, Julia; Luo, Yanjia; Li, Ya-Dong; Quintanilla, Luis; Li, Yongyi; Xu, Chongchong; Wen, Zhexing; Song, Juan; Jin, Jian; Deshmukh, Mohanish

Chen, Xian; Xie, Ling; Sheehy, Ryan; Xiong, Yan; Muneer, Adil; Wrobel, John; Park, Kwang-Su; Liu, Jing; Velez, Julia; Luo, Yanjia; Li, Ya-Dong; Quintanilla, Luis; Li, Yongyi; Xu, Chongchong; Wen, Zhexing; Song, Juan; Jin, Jian; Deshmukh, Mohanish.

Affiliation

Chen X; University of North Carolina at Chapel Hill.
Xie L; University of North Carolina at Chapel Hill.
Sheehy R; University of North Carolina.
Xiong Y; Icahn School of Medicine at Mount Sinai.
Muneer A; University of North Carolina at Chapel Hill.
Wrobel J; UNC-Chapel Hill.
Park KS; Icahn School of Medicine at Mount Sinai.
Liu J; Icahn School of Medicine at Mount Sinai.
Velez J; Icahn School of Medicine at Mount Sinai.
Luo Y; University of North Carolina at Chapel Hill.
Li YD; University of North Carolina at Chapel Hill.
Quintanilla L; University of North Carolina at Chapel Hill.
Li Y; University of North Carolina at Chapel Hill.
Xu C; Emory University School of Medicine.
Wen Z; Emory University.
Song J; University of North Carolina at Chapel Hill.
Jin J; Icahn School of Medicine at Mount Sinai.
Deshmukh M; University of North Carolina.

Res Sq ; 2023 Nov 21.

Article in En | MEDLINE | ID: mdl-38045363

Key words

AD cognitive and noncognitive symptoms; AD diagnosis biomarkers; AD pathogenesis; blood-brain barrier (BBB); brain-penetrant inhibitor; companion diagnosis; mechanism of drug action; mechanism-based therapy; mouse-human conservation; noncanonical translational mechanism; proteomics; proteopathology; signaling pathways

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google